Early trial tests new drug mix to boost stem cell harvest for cancer transplant
NCT ID NCT03909412
Summary
This early-phase study is testing the safety of a new drug combination used to collect a patient's own stem cells for a transplant. The goal is to find the highest safe dose of the drug carfilzomib when used with other standard medications for this collection process. The study will enroll about 18 adults with multiple myeloma who have already received some treatment and are eligible for a stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hackensack Meridian Health - John Theurer Cancer Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.